[go: up one dir, main page]

DK1113787T3 - Agitationsuafhængige farmaceutiske multipelenhedsretardformuleringer og fremgangsmåde til deres fremstilling - Google Patents

Agitationsuafhængige farmaceutiske multipelenhedsretardformuleringer og fremgangsmåde til deres fremstilling

Info

Publication number
DK1113787T3
DK1113787T3 DK99948770T DK99948770T DK1113787T3 DK 1113787 T3 DK1113787 T3 DK 1113787T3 DK 99948770 T DK99948770 T DK 99948770T DK 99948770 T DK99948770 T DK 99948770T DK 1113787 T3 DK1113787 T3 DK 1113787T3
Authority
DK
Denmark
Prior art keywords
agitation
preparation
methods
multiple unit
retardant formulations
Prior art date
Application number
DK99948770T
Other languages
Danish (da)
English (en)
Inventor
Venkata-Rangarao Kanikanti
Roland Rupp
Erich Brendel
Claus Weisemann
Ernst Chantraine
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Application granted granted Critical
Publication of DK1113787T3 publication Critical patent/DK1113787T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nonmetallic Welding Materials (AREA)
  • General Preparation And Processing Of Foods (AREA)
DK99948770T 1998-09-18 1999-09-17 Agitationsuafhængige farmaceutiske multipelenhedsretardformuleringer og fremgangsmåde til deres fremstilling DK1113787T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19842753A DE19842753A1 (de) 1998-09-18 1998-09-18 Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
DK1113787T3 true DK1113787T3 (da) 2004-05-17

Family

ID=7881376

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99948770T DK1113787T3 (da) 1998-09-18 1999-09-17 Agitationsuafhængige farmaceutiske multipelenhedsretardformuleringer og fremgangsmåde til deres fremstilling

Country Status (29)

Country Link
US (1) US6805881B1 (fr)
EP (1) EP1113787B1 (fr)
JP (1) JP2002526437A (fr)
KR (1) KR100660072B1 (fr)
CN (1) CN1178650C (fr)
AT (1) ATE260645T1 (fr)
AU (2) AU5861499A (fr)
BG (1) BG105325A (fr)
BR (1) BR9913839A (fr)
CA (1) CA2344372C (fr)
DE (2) DE19842753A1 (fr)
DK (1) DK1113787T3 (fr)
EE (1) EE04700B1 (fr)
ES (1) ES2215404T3 (fr)
HK (1) HK1040932B (fr)
HR (1) HRP20010198A2 (fr)
HU (1) HUP0103669A3 (fr)
ID (1) ID28735A (fr)
IL (2) IL141532A0 (fr)
NO (1) NO20011211L (fr)
NZ (1) NZ510563A (fr)
PL (1) PL195543B1 (fr)
PT (1) PT1113787E (fr)
RU (1) RU2235540C2 (fr)
SK (1) SK285099B6 (fr)
TR (1) TR200100756T2 (fr)
UA (1) UA73097C2 (fr)
WO (2) WO2000016747A1 (fr)
ZA (1) ZA200101485B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20020044962A1 (en) * 2000-06-06 2002-04-18 Cherukuri S. Rao Encapsulation products for controlled or extended release
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
AR034813A1 (es) † 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
JP2008525313A (ja) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
EP1685841A1 (fr) * 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention et traitement de troubles thromboemboliques
DE102005012561B4 (de) 2005-03-18 2008-06-19 Christian Beer Verfahren zum Betrieb eines Werkstück-Transfersystems
DE102005045518A1 (de) * 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
WO2007039132A1 (fr) 2005-10-04 2007-04-12 Bayer Healthcare Ag Nouvelle forme polymorphe et forme amorphe de 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
CN100448432C (zh) * 2006-10-26 2009-01-07 徐竹青 高溶出度尼莫地平分散片的制备方法
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US7952167B2 (en) * 2007-04-27 2011-05-31 Taiwan Semiconductor Manufacturing Company, Ltd. Scribe line layout design
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
MA33060B1 (fr) * 2009-01-28 2012-02-01 Novartis Ag Formulations galéniques de composés organiques
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
ES2665467T3 (es) 2010-03-29 2018-04-25 Astellas Pharma Inc. Composición farmacéutica de liberación modificada
WO2023080910A1 (fr) * 2020-11-18 2023-05-11 Fb-Hrs, Llc Compositions contenant du dofétilide et de la mexilétine et leurs utilisations
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5482525A (en) 1977-12-13 1979-06-30 Aisan Ind Co Ltd Exhaust gas recirculation system
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4449983A (en) 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
SE455836B (sv) * 1985-10-11 1988-08-15 Haessle Ab Beredning med kontrollerad frisettning innehallande ett salt av metoprolol samt metod for framstellning av denna beredning
DE3612212A1 (de) 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
DE3612211A1 (de) 1986-04-11 1987-10-15 Basf Ag Kontinuierliches verfahren zum tablettieren
JPS63222121A (ja) * 1987-03-10 1988-09-16 Nippon Soda Co Ltd 徐放性ゲル製剤
DE3720757A1 (de) 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
JPH02174722A (ja) * 1988-09-01 1990-07-06 Kureha Chem Ind Co Ltd かわらたけ由来の蛋白多糖体の粒状製剤
DE3830353A1 (de) 1988-09-07 1990-03-15 Basf Ag Verfahren zur kontinuierlichen herstellung von festen pharmazeutischen formen
JPH03101615A (ja) * 1989-09-14 1991-04-26 Sumitomo Pharmaceut Co Ltd 胃内滞留型持続性製剤
JPH03145418A (ja) 1989-10-27 1991-06-20 Sumitomo Pharmaceut Co Ltd 塩基性薬物塩酸塩の徐放性製剤
JP3078859B2 (ja) * 1990-02-23 2000-08-21 武田薬品工業株式会社 安定な放出制御性製剤用コーティング剤
ATE159426T1 (de) 1991-04-16 1997-11-15 Nippon Shinyaku Co Ltd Verfahren zur herstellung einer festen dispersion
DE4138513A1 (de) 1991-11-23 1993-05-27 Basf Ag Feste pharmazeutische retardform
JP3059004B2 (ja) * 1992-09-18 2000-07-04 ダイセル化学工業株式会社 アルカリ水溶液に対する溶解性の高い低置換度ヒドロキシプロピルセルロース及びその製造法
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
SE9402422D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New beads for controlled release and a pharmaceutical preparation containing the same
FR2725624B1 (fr) 1994-10-14 1997-01-17 Jouveinal Inst Rech Procede de preparation de formes pharmaceutiques a liberation controlee
DE19504831A1 (de) 1995-02-14 1996-09-05 Basf Ag Feste Wirkstoffzubereitungen enthaltend Hydroxypropylcellulose

Also Published As

Publication number Publication date
EE200100161A (et) 2002-08-15
NO20011211D0 (no) 2001-03-09
EP1113787B1 (fr) 2004-03-03
NZ510563A (en) 2002-10-25
HK1040932B (zh) 2005-08-05
CA2344372C (fr) 2009-12-22
PL195543B1 (pl) 2007-09-28
KR100660072B1 (ko) 2006-12-22
NO20011211L (no) 2001-03-09
EE04700B1 (et) 2006-10-16
JP2002526437A (ja) 2002-08-20
WO2000016748A1 (fr) 2000-03-30
DE19842753A1 (de) 2000-03-23
ES2215404T3 (es) 2004-10-01
ZA200101485B (en) 2002-02-22
SK285099B6 (sk) 2006-06-01
AU6191899A (en) 2000-04-10
AU750617B2 (en) 2002-07-25
KR20010073172A (ko) 2001-07-31
PT1113787E (pt) 2004-07-30
RU2235540C2 (ru) 2004-09-10
HRP20010198A2 (en) 2002-04-30
ID28735A (id) 2001-06-28
HUP0103669A3 (en) 2006-07-28
ATE260645T1 (de) 2004-03-15
SK3722001A3 (en) 2001-10-08
BR9913839A (pt) 2001-06-12
BG105325A (bg) 2001-11-30
HUP0103669A2 (hu) 2002-01-28
AU5861499A (en) 2000-04-10
TR200100756T2 (tr) 2001-07-23
CN1178650C (zh) 2004-12-08
IL141532A (en) 2007-03-08
CA2344372A1 (fr) 2000-03-30
US6805881B1 (en) 2004-10-19
PL346535A1 (en) 2002-02-11
HK1040932A1 (en) 2002-06-28
WO2000016747A1 (fr) 2000-03-30
IL141532A0 (en) 2002-03-10
EP1113787A1 (fr) 2001-07-11
UA73097C2 (en) 2005-06-15
DE59908764D1 (de) 2004-04-08
CN1317959A (zh) 2001-10-17

Similar Documents

Publication Publication Date Title
DK1113787T3 (da) Agitationsuafhængige farmaceutiske multipelenhedsretardformuleringer og fremgangsmåde til deres fremstilling
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
BR9503386A (pt) Formulaçao farmacêutica comprimido dispersivel e processo para a fabricaçao de comprimidos dispersíveis contendo cloridrato de fluoxetina
YU35893A (sh) Formulacije oksidona sa kontrolisanim otpuštanjem i njihova upotreba
ATE211907T1 (de) Osmotisches arzneimittelfreisetzungssystem
CA2427815A1 (fr) Preparations d'hydrocodone a liberation lente
EP1246622A4 (fr) Nouvelles formes posologiques de benzimidazole substitue
CA2326517A1 (fr) Nouvelles formes galeniques de meloxicame a administrer par voie orale
CA2330480A1 (fr) Preparation a liberation controlee de divalproex sodium
EP1622586A4 (fr) Procede pour la preparation de comprimes, gelules au autres formes solides de tannate
EP1460998A4 (fr) Comprime pharmaceutique de metformine a liberation prolongee
ATE177944T1 (de) Pellets
WO2003005967A3 (fr) Formulation a liberation double comportant un ester ethylique de levodopa et un inhibiteur de decarboxylase dans une couche a liberation instantanee avec un ester ethylique de levodopa et un inhibiteur de decarboxylase dans un noyau a liberation controlee
IS3789A7 (is) Aðferð við framleiðslu lyfjaskammta í föstu formimeð tempraðri losun virks þáttar
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
BR9608392A (pt) Preparação multiparticulada de liberação controlada e forma de dosagem em tablete.
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
BRPI0307319B8 (pt) forma de dosagem oral para liberação controlada de droga e processo para sua preparação
PT1121109E (pt) Formulacao bifasica contendo tramadol
PT1190712E (pt) Composicao de esferas de tramadol para administracao oral uma vez por dia